🇺🇸
SHAOXING, China, Oct. 25, 2026 /PRNewswire/ — At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. (“Wenda Pharma”) will publish the phase II clinical trial data for NHWD-870 HCl, an oral BET inhibitor, in Chinese patients with advanced NUT carcinoma (NC)….
Source: prnewswire
Country: United States